• Wed news: BioNTech buying Biotheus. FDA’s Califf lists hopes for his successor. Amgen loses $12B market cap from hidden spreadsheet tab. TRex Bio raises $84M. London is Europe’s life science capitol. See more on our front page

FDA asks advisers to review Lynparza amid growing scrutiny of PARP drugs

Quote
cafead

cafead

Administrator
Staff member
  • cafead   Mar 05, 2023 at 03:22: PM
via The Food and Drug Administration will convene an expert panel in April to review use Merck & Co. and AstraZeneca’s Lynparza in patients newly diagnosed with advanced prostate cancer, the companies said Thursday.

article source
 




Top Bottom
Back
Quote